SPRB: Spruce Biosciences, Inc. Company Short-Term Debt

Symbol and logo of brand Spruce Biosciences (SPRB)

High R&D costs and previous clinical failures have weakened the defensive position of Spruce Biosciences (SPRB), whose patents require renewal. The business relies on developing treatments for endocrine pathologies, yet faces uncertainty regarding final tests and a heavy reliance on a single product. This price chart, where the metric stands at 0.00, is further complemented by the importance of strict distribution within the hospital sector to preserve the properties of the medications.

SPRB (sprucebiosciences.com) Company Short-Term Debts history from 07/04/2022 to 10/29/2026

SPRB (Spruce Biosciences Inc.): analytical breakdowns and indicator data

- current quotes and average value forecast:
Price Chart Spruce Biosciences, Inc.|SPRB - Fair Value Consensus
- market capitalization information:
Market Value Spruce Biosciences, Inc.|SPRB - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share Spruce Biosciences|SPRB - Book Capitalization|Market Cap to Net Assets Ratio sprucebiosciences.com|SPRB - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity Spruce Biosciences|SPRB - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Spruce Biosciences|SPRB - Company Cumulative Debt|Debt to Book Value Spruce Biosciences, Inc.|SPRB - Amount of Long-Term Liabilities|Company Short-Term Debts Spruce Biosciences
Basic company analysis:Spruce Biosciences, Inc. - SPRB
Mass-produced product of Spruce Biosciences Inc.

To ensure the uninterrupted supply of orphan drugs, Spruce Biosciences (SPRB) relies on strategic distributor reserves, which necessitates strict liquidity control. An analysis of the company's short-term credits and loans allows for an assessment of the business's ability to meet obligations within one year, weighing current cash flows against debt pressure to minimize capital freeze risks and confirm asset stability.

Who Spruce Biosciences competes with

ASND - Company Short-Term Debt|Company Short-Term Loans and Borrowings MDGL (Madrigal Pharmaceuticals Inc)|Corcept (CORT) - Company Short-Term Debt|Company Current Liabilities Rhythm Corp|AKRO (Akero Therapeutics) - Company Short-Term Debts|Company Short-Term Debts metsera.com|Company Current Liabilities MLTX (MoonLake)|CRNX (Crinetics Pharmaceuticals, Inc.) - Company Short-Term Loans and Borrowings|Company Short-Term Debt NewAmsterdam Pharma N.V. NAMS|SLNO - Company Current Liabilities|Amicus Therapeutics - Company Short-Term Debts|Short-Term Debt 89bio.com|AGIO (Agios Pharmaceuticals, Inc.) - Company Current Liabilities|GPCR: Amount of Current Liabilities|MDXG (MiMedx Group) - Company Short-Term Debts|Company Short-Term Debts Rezolute Bio|Company Short-Term Debts LXRX|Company Short-Term Debt MBX (mbxbio.com)|Company Short-Term Debt Altimmune ALT|Aardvark Therapeutics Inc. (AARD) - Short-Term Debt|SGMT - Company Short-Term Debt|BIOA: Company Short-Term Debt|BMEA: Company Short-Term Debts|QNCX - Short-Term Debt Volume|Company Short-Term Debt Fractyl Health|vTv Therapeutics Inc (VTVT) - Short-Term Debt Volume|Company Short-Term Debt Agape ATP Corporation (ATPC)|Company Current Liabilities pluri-biotech.com PLUR|Company Short-Term Debt Synlogic SYBX|Short-Term Debt Volume lipocine.com (LPCN)|MTNB - Company Short-Term Debt|Current Liabilities GLTO|Carmell Corp (CTCX) - Company Short-Term Debt|Lumos Therapeutics - Company Short-Term Loans and Borrowings|Company Current Liabilities ONVO|Company Short-Term Debts radiuspharm.com